Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
Introduction: The RATIONALE-309 trial confirmed the significant efficacy and safety of tislelizumab plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). However, the economic benefits of this regimen are unclear. Therefore, this study aimed to evaluate the c...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Veröffentlicht: |
Frontiers Media S.A.,
2023-10-01T00:00:00Z.
|
| Schlagworte: | |
| Online-Zugang: | Connect to this object online. |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Online
Connect to this object online.3rd Floor Main Library
| Signatur: |
A1234.567 |
|---|---|
| Exemplar 1 | Verfügbar |